Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

Vaccine

Volumn 28, Issue 45, 2010, Pages 7331-7336

  Black, Steven ^a   Della Cioppa, Giovanni ^b   Malfroot, Anne ^c   Nacci, Pantaleo ^b   Nicolay, Uwe ^d   Pellegrini, Michele ^b   Sokal, Etienne ^e   Vertruyen, André ^f  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d Global Clinical Research and Development   (Germany)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f Pediatrics Department Sint Vincentiushospital GZA Group   (Belgium)

Author keywords

Adolescents; Children; Influenza vaccine; MF59 adjuvant

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ADOLESCENT; ARTICLE; ASTHMA; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CRYING; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; EYE DISEASE; FATIGUE; GASTROENTERITIS; GROUPS BY AGE; HUMAN; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE TENDERNESS; IRRITABILITY; MALAISE; OROPHARYNGEAL PAIN; OTITIS MEDIA; PAIN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VACCINATION REACTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; POLYSORBATES; SQUALENE;

EID: 77957755419     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.075     Document Type: Article

References (25)

1. Esposito S., Marchisio P., Principi N. The global state of influenza in children. Pediatr Infect Dis J 2008, 27(11 Suppl.):S149-S153.
2. Esposito S., Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009, 22:244-249.
3. Centers for Disease Control and Prevention. Flu activity & surveillance. 2007-08 U.S. influenza season summary. Available from URL: [accessed 03.03.10]. http://www.cdc.gov/flu/weekly/weeklyarchives2007-2008/07-08summary.htm.
4. Centers for Disease Control and Prevention. Flu activity & surveillance. Fluview influenza surveillance report. 2009-2010 influenza season week 3 ending January 23, 2010. Available from URL: [accessed 03.03.10]. http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/weekly03.htm.
5. Principi N., Esposito S., Marchisio P., Gasparini R., Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003, 22(10 Suppl.):S207-S210.
6. Centers for Disease Control and Prevention. Influenza: vaccination. Available from URL: [accessed 03.03.10]. http://www.cdc.gov/nchs/fastats/flu.htm.
7. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, (2):CD004879.
8. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28(7):563-571.
9. Libster R., Bugna J., Coviello S., Hijano D.R., Dunaiewsky M., Reynoso N., et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010, 362(1):45-55.
10. Kumar A., Zarychanski R., Pinto R., Cook D.J., Marshall J., Lacroix J., et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302(17):1872-1879.
11. Donaldson L.J., Rutter P.D., Ellis B.M., Greaves F.E., Mytton O.T., Pebody R.G., et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009, 339:b5213.
12. Baldo V., Baldovin T., Floreani A., Fragapane E., Trivello R., Family Medicine Group Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007, 27(5):542-547.
13. Banzhoff A., Pellegrini M., Del Giudice G., Fragapane E., Groth N., Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses 2008, 2(6):243-249.
14. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009, 106(10):3877-3882.
15. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
16. Dormitzer P.R., Rappuoli R., Casini D., O'Hagan D., Runham C., Montomoli E., et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Curr Influenza 2009, RRN1025.
17. Wraith D.C., Goldman M., Lambert P.H. Vaccination and autoimmune disease: what is the evidence?. Lancet 2003, 362(9396):1659-1666.
18. Stowe J., Andrews N., Wise L., Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009, 169(3):382-388.
19. Carlson B.C., Jansson Å.M., Larsson A., Bucht A., Lorentzen J.C. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000, 156(6):2057-2065.
20. Holm B.C., Svelander L., Bucht A., Lorentzen J.C. The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes. Clin Exp Immunol 2002, 127(3):430-435.
21. Satoh M., Kuroda Y., Yoshida H., Behney K.M., Mizutani A., Akaogi J., et al. Induction of lupus autoantibodies by adjuvants. J Autoimmun 2003, 21(1):1-9.
22. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27(45):6291-6295.
23. Pellegrini M., Nicolay U., Lindert K., Groth N., Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009, 27(49):6959-6965.
24. Cintra O.A., Rey L.C. Safety, immunogenicity and efficacy of influenza vaccine in children. J Pediatr (Rio J) 2006, 82(3 Suppl.):S83-S90.
25. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Andreani T., Podda A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17(2):99-104.